SE436882B - 1h-pyrrolo /2,1-c//1,4/bensodiazepin-2-akrylamidforeningar, forfarande for deras framstellning och farmaceutisk komposition - Google Patents
1h-pyrrolo /2,1-c//1,4/bensodiazepin-2-akrylamidforeningar, forfarande for deras framstellning och farmaceutisk kompositionInfo
- Publication number
- SE436882B SE436882B SE8001458A SE8001458A SE436882B SE 436882 B SE436882 B SE 436882B SE 8001458 A SE8001458 A SE 8001458A SE 8001458 A SE8001458 A SE 8001458A SE 436882 B SE436882 B SE 436882B
- Authority
- SE
- Sweden
- Prior art keywords
- group
- compound
- benzodiazepine
- pyrrolo
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- PCJZRPDVONTWOJ-UHFFFAOYSA-N 3-(1,2-benzodiazepin-2-yl)prop-2-enamide Chemical compound NC(=O)C=CN1C=CC=C2C=CC=CC2=N1 PCJZRPDVONTWOJ-UHFFFAOYSA-N 0.000 title description 5
- 239000000126 substance Substances 0.000 title description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- -1 [1,4] benzodiazepine-2-acrylamide compound Chemical class 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 17
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 229910052783 alkali metal Inorganic materials 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 150000003464 sulfur compounds Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 125000000626 sulfinic acid group Chemical group 0.000 claims description 3
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 claims description 2
- RMGVZKRVHHSUIM-UHFFFAOYSA-N dithionic acid Chemical compound OS(=O)(=O)S(O)(=O)=O RMGVZKRVHHSUIM-UHFFFAOYSA-N 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 229910001882 dioxygen Inorganic materials 0.000 claims 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- 239000013078 crystal Substances 0.000 description 13
- BIVATAPISXAMKP-UHFFFAOYSA-N 3-(1h-1,4-benzodiazepin-2-yl)prop-2-enamide Chemical compound N1C(C=CC(=O)N)=CN=CC2=CC=CC=C21 BIVATAPISXAMKP-UHFFFAOYSA-N 0.000 description 11
- 238000000862 absorption spectrum Methods 0.000 description 11
- 238000000921 elemental analysis Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- JMXYWJDVOYLZCK-UHFFFAOYSA-N 3-(5-acetyl-4-hydroxy-6-methoxy-3-methyl-11-oxo-6a,7-dihydro-6h-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)prop-2-enamide Chemical compound CC(=O)N1C(OC)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C21 JMXYWJDVOYLZCK-UHFFFAOYSA-N 0.000 description 1
- POIGNADHWUFNSO-UHFFFAOYSA-N 8-(3-amino-3-oxoprop-1-enyl)-4-carbamoyloxy-3-methyl-11-oxo-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepine-6-sulfonic acid Chemical compound N1C(S(O)(=O)=O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(OC(N)=O)=C12 POIGNADHWUFNSO-UHFFFAOYSA-N 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000004285 Potassium sulphite Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000258976 Streptomyces refuineus Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OKSVAHOCLSHREQ-UHFFFAOYSA-L [Na+].C(N)(=O)OC1=C(C=CC=2C(N3C(C(NC=21)S(=O)[O-])CC(=C3)C=CC(=O)[NH-])=O)C.[Na+] Chemical compound [Na+].C(N)(=O)OC1=C(C=CC=2C(N3C(C(NC=21)S(=O)[O-])CC(=C3)C=CC(=O)[NH-])=O)C.[Na+] OKSVAHOCLSHREQ-UHFFFAOYSA-L 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- WVHBHPATSLQXGC-UHFFFAOYSA-N benzene;ethanol Chemical compound CCO.C1=CC=CC=C1 WVHBHPATSLQXGC-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- CBSHRSXXAZQEGH-UHFFFAOYSA-M sodium 3-(1,2-benzodiazepin-2-yl)prop-2-enoylazanide Chemical compound [Na+].N=1N(C=CC=C2C=1C=CC=C2)C=CC(=O)[NH-] CBSHRSXXAZQEGH-UHFFFAOYSA-M 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 229940075931 sodium dithionate Drugs 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8988679A JPS5615289A (en) | 1979-07-17 | 1979-07-17 | Novel benzodiazepinnbased compound 3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8001458L SE8001458L (sv) | 1981-01-18 |
| SE436882B true SE436882B (sv) | 1985-01-28 |
Family
ID=13983232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8001458A SE436882B (sv) | 1979-07-17 | 1980-02-25 | 1h-pyrrolo /2,1-c//1,4/bensodiazepin-2-akrylamidforeningar, forfarande for deras framstellning och farmaceutisk komposition |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4309437A (member.php) |
| JP (1) | JPS5615289A (member.php) |
| BE (1) | BE882305A (member.php) |
| CA (1) | CA1152985A (member.php) |
| CH (1) | CH648848A5 (member.php) |
| DE (1) | DE3010544C2 (member.php) |
| FR (1) | FR2461711A1 (member.php) |
| GB (1) | GB2053894B (member.php) |
| LU (1) | LU82272A1 (member.php) |
| NL (1) | NL8001531A (member.php) |
| SE (1) | SE436882B (member.php) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1214774A (en) * | 1983-02-10 | 1986-12-02 | Yusei Shiraga | Benzodiazepine derivative |
| JPS59152329A (ja) * | 1983-02-17 | 1984-08-31 | Green Cross Corp:The | 局所障害抑制剤 |
| JPS60168512U (ja) * | 1985-03-25 | 1985-11-08 | 株式会社栗田機械製作所 | 圧搾濾板の圧搾膜検査装置 |
| GB9818730D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| EP1413582B1 (en) * | 1998-08-27 | 2006-03-15 | Spirogen Limited | Dimeric pyrrolobenzodiazepines |
| GB9818732D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| GB9818731D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| GB0226593D0 (en) * | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0321295D0 (en) * | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| GB0404577D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| JP4909258B2 (ja) * | 2004-03-01 | 2012-04-04 | スピロゲン リミティッド | Ｃ２置換ピロロベンゾジアゼピン類を調製するための主要な中間体としての１１−ヒドロキシ−５Ｈ−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−５−オン誘導体 |
| GB0404578D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US7528126B2 (en) * | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
| AU2006238686B2 (en) * | 2005-04-21 | 2011-10-06 | Medimmune Limited | Pyrrolobenzodiazepines |
| GB0813432D0 (en) * | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| BR112012026410B8 (pt) | 2010-04-15 | 2023-01-31 | Spirogen Dev Sarl | Composto e conjugado de pirrolobenzodiazepinas e usos dos mesmos |
| CN107019804A (zh) | 2010-04-15 | 2017-08-08 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| CN103987718A (zh) | 2011-09-20 | 2014-08-13 | 斯皮罗根有限公司 | 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓 |
| KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
| WO2013053872A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| AU2012322932B2 (en) | 2011-10-14 | 2016-11-10 | Medimmune Limited | Pyrrolobenzodiazepines |
| CN103987384A (zh) | 2011-10-14 | 2014-08-13 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| IN2014MN02175A (member.php) | 2012-04-30 | 2015-08-28 | Ucl Business Plc | |
| SMT201800346T1 (it) | 2012-10-12 | 2018-09-13 | Medimmune Ltd | Coniugati pirrolobenzodiazepina-anticorpo |
| EP2839860B1 (en) | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| RS57694B1 (sr) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Pirolobenzodiazepin - anti-psma konjugati antitela |
| KR101995619B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
| JP6367204B2 (ja) | 2012-10-12 | 2018-08-01 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 結合用のピロロベンゾジアゼピン誘導体の合成および中間体 |
| SMT202100265T1 (it) | 2012-10-12 | 2021-07-12 | Medimmune Ltd | Pirrolobenzodiazepine e loro coniugati |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| PL2906251T3 (pl) | 2012-10-12 | 2018-02-28 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22 |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| TW201808936A (zh) | 2016-05-18 | 2018-03-16 | 美商梅爾莎納醫療公司 | 吡咯并苯并二氮呯類及其共軛物 |
| EP3475284B1 (en) | 2016-06-24 | 2022-11-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| JP6671555B2 (ja) | 2017-02-08 | 2020-03-25 | アーデーセー セラピューティクス ソシエテ アノニム | ピロロベンゾジアゼピン抗体複合体 |
| CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
| MX2019012464A (es) | 2017-04-20 | 2019-12-11 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. |
| AU2018285562B2 (en) | 2017-06-14 | 2024-01-18 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| ES2906965T3 (es) | 2017-08-18 | 2022-04-21 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| ES2967878T3 (es) | 2019-03-15 | 2024-05-06 | Medimmune Ltd | Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer |
| USD925487S1 (en) * | 2019-10-22 | 2021-07-20 | Lg Electronics Inc. | Audio player |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3523941A (en) * | 1967-03-06 | 1970-08-11 | Hoffmann La Roche | Benzodiazepine compounds and process for their preparation |
| US3524849A (en) * | 1967-10-27 | 1970-08-18 | Hoffmann La Roche | Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein |
-
1979
- 1979-07-17 JP JP8988679A patent/JPS5615289A/ja active Granted
-
1980
- 1980-02-25 SE SE8001458A patent/SE436882B/sv not_active IP Right Cessation
- 1980-02-27 CA CA000346511A patent/CA1152985A/en not_active Expired
- 1980-03-04 US US06/127,984 patent/US4309437A/en not_active Expired - Lifetime
- 1980-03-10 GB GB8008033A patent/GB2053894B/en not_active Expired
- 1980-03-14 NL NL8001531A patent/NL8001531A/nl not_active Application Discontinuation
- 1980-03-19 LU LU82272A patent/LU82272A1/fr unknown
- 1980-03-19 BE BE0/199851A patent/BE882305A/fr not_active IP Right Cessation
- 1980-03-19 FR FR8006153A patent/FR2461711A1/fr active Granted
- 1980-03-19 DE DE3010544A patent/DE3010544C2/de not_active Expired
- 1980-03-20 CH CH2187/80A patent/CH648848A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE8001458L (sv) | 1981-01-18 |
| CA1152985A (en) | 1983-08-30 |
| GB2053894A (en) | 1981-02-11 |
| FR2461711A1 (fr) | 1981-02-06 |
| DE3010544C2 (de) | 1982-07-01 |
| CH648848A5 (de) | 1985-04-15 |
| US4309437A (en) | 1982-01-05 |
| BE882305A (fr) | 1980-07-16 |
| GB2053894B (en) | 1983-04-20 |
| DE3010544A1 (de) | 1981-01-29 |
| FR2461711B1 (member.php) | 1983-05-13 |
| LU82272A1 (fr) | 1980-07-01 |
| JPS5615289A (en) | 1981-02-14 |
| JPS6237631B2 (member.php) | 1987-08-13 |
| NL8001531A (nl) | 1981-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE436882B (sv) | 1h-pyrrolo /2,1-c//1,4/bensodiazepin-2-akrylamidforeningar, forfarande for deras framstellning och farmaceutisk komposition | |
| DE69412322T2 (de) | Xanthin-Derivate | |
| DE69522490T2 (de) | Platinkomplexe | |
| PT93743A (pt) | Processo para a preparacao de derivados organicos fosforados com actividade antivirus | |
| DE69533043T2 (de) | Acrylamid-derivate und verfahren zu deren herstellung | |
| AT394725B (de) | Verfahren zur herstellung von neuen mitomycin-c-analogen | |
| DE3413489C2 (member.php) | ||
| DE3447003C2 (de) | 7-Acylamino-9a-methoxymitosane, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel | |
| DE68914223T2 (de) | Mitomycinderivate. | |
| JPS63183596A (ja) | グルコシルモラノリン誘導体 | |
| DE2954197C2 (member.php) | ||
| EP0423012B1 (en) | Method of curing liver diseases by using pyrrolo quinoline quinone triesters and novel pyrrolo quinoline quinone triesters | |
| DE69624236T2 (de) | Ausgewählte lösliche ester von indolcarbazolen die hydroxyl enthalten | |
| EP0003788B1 (de) | Glucofuranosyl-nitrosoharnstoffderivate, Verfahren zu deren Herstellung und ihre pharmazeutischen Präparate | |
| US4748251A (en) | 7-n-aminomethylenemitomycin derivative | |
| EP0349928A2 (de) | Purinderivate | |
| EP2497765B1 (de) | Verfahren zur herstellung von kreatinamiden | |
| US5001158A (en) | Nitrosoureas compounds preparation thereof and utilization thereof in anticancerous | |
| EP0272063B1 (en) | Mitomycin derivatives | |
| DE3883434T2 (de) | Mitomycinanaloge, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen. | |
| US3912767A (en) | Novel sulfonate esters of 2-hydroxy-3-(methylthio)-1,4-naphthoquinone | |
| EP0588799B1 (de) | Neue sulfonamide, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten | |
| KR950013764B1 (ko) | 피로글루타미드 유도체, 그 제조방법, 및 그것을 함유하는 치매증 치료제 | |
| JPS6318590B2 (member.php) | ||
| DE4028666A1 (de) | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8001458-2 Effective date: 19880125 Format of ref document f/p: F |